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Sha Shen Mai Men Dong Tang (SMD-2; 沙參麥冬湯 sha shen mai dong tang) is a Chinese medicinal herb
(CMH; 中草藥 zhong cǎo yao) used to treat symptoms associated with cancer therapy. The objective of
this study was to assess the effect of SMD-2 on the levels of urinary copper (Cu), zinc (Zn), and selenium
(Se) in lung cancer patients and head and neck cancer patients receiving chemoradiotherapy. Forty-two
head and neck cancer patients and 10 lung cancer patients participated in our clinical trial. Each patient
received chemoradiotherapy for 4 weeks. In addition, each patient was treated with SMD-2 for 8 weeks,
including 2 weeks prior to and after the chemoradiotherapy treatment. Comparison of urinary Cu, Zn,
and Se levels and the ratios of Zn to Cu and Se to Cu at three time points in the two types of cancer were
assessed using the generalized estimating equations (GEEs). After the patients received chemo-
radiotherapy for 4 weeks, SMD-2 treatment was found to be associated with a signiﬁcant decrease in
urinary Cu levels, whereas urinary Zn and Se levels increased signiﬁcantly. In addition, the ratios of Zn to
Cu and Se to Cu in the urine samples of these patients also increased signiﬁcantly. Both the urinary Zn
levels and the ratio of Zn to Cu in head and neck cancer patients were signiﬁcantly higher than in lung
cancer patients. Urinary Zn and Se levels and the ratios of Zn to Cu and Se to Cu, but not urinary Cu levels,
increased signiﬁcantly during and after treatment when assessed using the GEE model. The SMD-2
treatments signiﬁcantly increased Zn and Se levels in the urine of head and neck cancer patients.
Increased Zn and Se levels in urine strengthened immune system.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
In Taiwan, the practice of using Chinese medicine in combina-
tionwithWesternmedicine to treat cancer patients is on the rise. In
this study, we treated head and neck as well as lung cancer patients
undergoing radiotherapy or chemotherapy with Sha Shen Mai Men
Dong Tang (SMD-2;沙參麥冬湯 sha shen mai dong tang), a mixture
of seven herbs. According to Chinese medicine, SMD-2 can “clearal and Occupational Health
55, Section 2, Linong Street,
for Food and Biomolecules,
molecules, National Taiwan Univeand nourish the lungs and stomach (清肺養胃 qıng fei yǎng wei)”,
“engender ﬂuid (生津 sheng jın)”, repair damaged cells, and control
the symptoms of dryness associated with cancer treatment.
Western cancer treatment depends solely on the use of radio-
therapy or chemotherapy, which unfortunately produces serious
side effects. Short-term side effects of chemoradiotherapy include
fatigue, nausea, vomiting, mucositis, myelosuppression, and neu-
tropenia. These side effects generally occur within months of
completion of chemotherapy.1 A variety of Chinese medicinal herbs
(CMHs; 中草藥 zhong cǎo yao) have been used to minimize these
side effects. A clinical study performed by Lan2 in China indicated a
signiﬁcant reduction in oral mucosal symptoms in nasopharyngeal
cancer patients who ﬁrst received chemoradiotherapy and then
SMD-2 treatments. Another study in China by Sung and Dong3
showed that head and neck cancer patients who receivedrsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
Table 1
Urinary Cu, Zn, and Se levels (mg/L) and ratios of Zn/Cu and Se/Cu prior to, during,
and after the SMD-2 treatment in patients with cancer of the head and neck
(N ¼ 42).
Prior to
treatment
During
treatment
After treatment p1* p2**
Cu 33.95 ± 52.00 18.82 ± 20.47 8.33 ± 6.81 <0.001 <0.001
Zn 212.2 ± 274.1 491.79 ± 718.8 790.8 ± 863.0 <0.001 <0.001
Se 37.44 ± 35.74 67.33 ± 59.45 115.83 ± 862.99 <0.001 <0.001
Zn/Cu 11.01 ± 15.30 32.72 ± 39.27 122.14 ± 114.37 <0.001 <0.001
Se/Cu 2.08 ± 2.20 4.84 ± 301 20.80 ± 16.46 <0.001 <0.001
*p1 was calculated using paired t test between the periods prior to and during
treatment.
**p2 was calculated using paired t test between the periods prior to and after
treatment.
SMD-2 ¼ Sha Shen Mai Men Dong Tang.
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chewing and swallowing. The patients were then treated with
SMD-2, and their symptoms improved tremendously.
Previous studies have shown that ﬂuctuations in the levels of Se,
Zn, and Cu in humans are indicators of cancer.4,5 For example, high
serum Cu levels and low serum Zn levels are markers of lung
cancer.6 Songchitsomboon et al7 suggested that the use of serum Cu
to Zn ratios as markers for the diagnosis of cancer or for staging
tumors must be interpreted with caution. A double-blind, ran-
domized study conducted by Lin et al8 indicated that after head and
neck cancer patients received chemoradiotherapy, Zn supplements
repair cellular DNA, strengthen the immune system, and alleviate
the severity of mucositis and dermatitis. As mentioned earlier, the
levels of Zn, Se, and Cu ﬂuctuate in cancer patients; therefore,
monitoring the levels of these trace elements during cancer treat-
ment may help in understanding the efﬁcacy of cancer treatment,
as well as provide an important tool in the diagnosis of cancer. The
objective of this study was to assess the effect of SMD-2 on changes
in urinary Cu, Zn, and Se levels in lung cancer patients and head and
neck cancer patients receiving chemoradiotherapy.
2. Materials and methods
2.1. Study design and participant selection
Measurements of urinary Cu, Zn, and Se levels were obtained
prior to and after SMD-2 treatment. This protocol was approved by
the Institutional Review Board in China Medical University, and
informed consent was obtained from patients prior to their
participation. Ten lung cancer patients and 42 head and neck cancer
patients participated in our study, which was conducted at a
medical center in central Taiwan. Each patient was advised by
medical personnel to take vitamins containing Zn and Se. Because
of ethical considerations, a placebo group was not included in the
study design. Each cancer patient was treated with radiotherapy
(average dose, 5440 cGy) and chemotherapy (cisplatin, 60 mg/m2
on Day 1; 5-ﬂuorouracil, 500 mg/m2/day on Days 1e5; and mito-
mycin C, 6 mg/m2/day on Day 1 and Day 8) for 4 weeks. In addition,
each patient received SMD-2 treatments for 8 weeks (2 weeks prior
to receiving chemoradiotherapy, 4 weeks during chemo-
radiotherapy, and 2 weeks after the treatment). SMD-2 is a powder
made of Adenophorae radix (南沙參 nan sha shen), Ophiopogon
tuber (麥門冬mai men dong), Polygonatum ofﬁcinale rhizome (玉竹
yù zhú), folium mori (桑葉 sang ye), Trichosanthes root (天花粉 tian
hua fen), semen dolichoris (白扁豆bai biǎn dou), Polygonatum
odoratum (葳蕤wei ruí), and Glycyrrhiza radix (甘草 gan cǎo). SMD-
2 is prepared by a manufacturer in Taiwan with good
manufacturing practices. We characterized SMD-2 with inductively
coupled plasma/mass spectrometry (ICP/MS) and found it to
contain Cu (27.6 ppm), Zn (85.7 ppm), and Se (0.38 ppm).
2.2. Measurement
Fresh spot urine samples were obtained from each cancer pa-
tient at three points during the trial (prior to, during, and after
chemoradiotherapy). Specimens were stored at 70C until metal
analysis was carried out. An ICP/MS instrument (PerkinElmer ELAN
DRC-e, Waltham, Massachusetts, US) was used to measure the Cu,
Zn, and Se levels. Jones9 and Heitland and K€oster10 have described
this procedure in detail. The methodology for metal analysis and
quality control has been published previously. The instrument
detection limit for Cu, Zn, and Se using ICP/MS was 0.16 mg/L,
0.48 mg/L, and 0.29 mg/L, respectively. The method detection limits
for Cu, Zn, and Se were 0.17 mg/L, 2.53 mg/L, and 0.30 mg/L, respec-
tively. The precision (relative standard deviation) of measuringurinary metals was less than 5%. The recovery for measuring uri-
nary metals was 106% for Cu, 102% for Zn, and 104% for Se.2.3. Data collection and analysis
After measuring urinary metal levels, we calculated the ratios of
Zn to Cu (Zn/Cu ratio) and Se to Cu (Se/Cu ratio). Data were
collected using Microsoft Excel 2000 (Microsoft, Redmond, WA,
USA) and analyzed by SPSS version 17.0 (SPSS, Inc., Chicago, IL,
USA). Because the sample size in this study was limited, the
nonparametric method was used. The differences in urinary metal
levels (mg/L) for each intervention period were examined using the
ManneWhitney U test (p < 0.05). The urinary Cu, Zn, and Se levels
and the ratios of Zn/Cu and Se/Cu in the two types of cancer at
three-stage points were compared using the generalized esti-
mating equations (GEEs).3. Results
Table 1 presents the urinary Cu, Zn, and Se levels prior to, during,
and after the treatment in patients with cancer of the head and neck
who were treated using SMD-2. The level of Cu in the urine of these
patients decreased to 25 mg/L after the treatment; however, the uri-
nary Zn and Se levels increased to 578 mg/L and 78 mg/L, respectively,
after the treatment. Furthermore, the Zn/Cu and Se/Cu ratios in the
urine of these patients increased 111 times and 18 times, respectively.
Table 2 presents the urinary Cu, Zn, and Se levels prior to, dur-
ing, and after the treatment in patients with lung cancer who were
treated using SMD-2. Prior to treatment, the urinary Cu level in
these patients was 25.9 mg/L on average, but after the treatment, the
average urinary Cu level decreased to 8.55 mg/L, which was statis-
tically signiﬁcant. Furthermore, the urinary Zn levels increased by
more than threefold after the treatment, and urinary Se levels
doubled after the treatment, both of which were also statistically
signiﬁcant. In addition, the Zn/Cu and Se/Cu ratios in the urine of
these patients increased signiﬁcantly.
Table 3 presents a comparison of the urinary Cu, Zn, and Se
levels and the ratios of Zn/Cu and Se/Cu in the two types of cancer
at three time points using the GEE model. There was no signiﬁcant
difference in urinary Cu levels in patients suffering from the two
types of cancer. Both urinary Zn levels and the ratio of Zn/Cu in
patients with head and neck cancer were signiﬁcantly higher than
in those with lung cancer. However, there was no signiﬁcant dif-
ference in the urinary Cu and Se levels (mg/L), or in the ratio of Se/Cu
between the groups of cancer patients. In addition, urinary Zn and
Se levels (mg/L) and the ratios of Zn/Cu and Se/Cu, but not urinary
Cu levels, increased signiﬁcantly during and after the treatment.
Table 2
Urinary Cu, Zn, and Se levels (mg/L) and ratios of Zn/Cu and Se/Cu prior to, during,
and after the SMD-2 treatment in patients with lung cancer (N ¼ 10).
Prior to
treatment
During
treatment
After treatment p1* p2**
Cu 25.93 ± 30.64 18.78 ± 21.36 8.55 ± 7.44 0.008 0.003
Zn 50.90 ± 38.23 66.94 ± 77.60 164.73 ± 96.65 0.013 0.003
Se 29.45 ± 24.58 41.42 ± 26.98 69.75 ± 31.88 0.021 0.003
Zn/Cu 4.89 ± 7.90 8.01 ± 9.43 30.82 ± 21.78 0.003 0.003
Se/Cu 1.80 ± 1.20 4.14 ± 3.56 13.97 ± 8.99 0.003 0.003
*p1 was calculated using paired t test between the periods prior to and during
treatment.
**p2 was calculated using paired t test between the periods prior to and after
treatment.
SMD-2 ¼ Sha Shen Mai Men Dong Tang.
T.-Y. Lai, H.-W. Kuo / Journal of Traditional and Complementary Medicine 6 (2016) 135e139 1374. Discussion
Our study showed that, in cancer patients who received 8 weeks
of SMD-2 treatments and 4 weeks of chemoradiotherapy, the uri-
nary Zn and Se levels and the ratios of Zn/Cu and Se/Cu increased
signiﬁcantly. Conversely, urinary Cu levels decreased signiﬁcantly
during and after treatment. SMD-2 contains the following eight
ingredients: hyacinth bean (白扁豆bai biǎn dou), Trichosanthes root
(天花粉 tian hua fen), Polygonati ofﬁcinalis rhizoma (玉竹 yù zhú)
Polygonatum odoratum (葳蕤 wei ruí), Adenophorae radix (南沙參
nan sha shen), folium mori (桑葉 sang ye), Ophiopogon tuber (麥門
冬 mai men dong), and Glycyrrhiza radix (甘草 gan cǎo)
Traditional indications for SMD-2 include a dry throat, thirst,
and a hacking cough with little sputum. Cancer patients' lungs are
often deﬁcient in “Yin (陰 yın)”which results in the aforementioned
symptoms. Glehnia root is used to “clear the lungs and activate Yin
(養陰清肺 yǎng yın qıng fei)”which “strengthens the stomach (健胃
jian wei)” and “promotes the production of bodily ﬂuids (生津
sheng jın)”. Ophiopogon root tuber is used to “nourish the Yin,
preventing the lungs from becoming too dry (滋陰潤肺 zı yın rùn
fei)”, and “remove excess heat from the heart (清心熱 qıng xın re)”,
as well as to help people relax.
SMD-2 treatments are beneﬁcial to cancer patients who receive
radiotherapy because Zn promotes collagen synthesis and epithe-
lialization, both of which are associated with the healing process.
Zn-binding proteins can be sequestered by mucosal cells and
transferred to albumin molecules on the serous site of the mucosal
cell membrane. However, Cu can interfere with Zn absorption by
competing for binding sites on the albumin molecule.11,12 The
chemopreventive properties of Se may be responsible for the
anticancer effects of compounds containing this element.
Chemoradiotherapy damages cell membranes and harms the
immune system in most cancer patients. In our study, every head
and neck cancer patient who received chemoradiotherapyTable 3
Comparison of the urinary Cu, Zn, and Se levels (mg/L) and ratios of Zn/Cu and Se/Cu in
equation model.
Cu
b (SE)
Zn
b (SE)
Cancer types
Head and neck 3.03 (8.28) 393.9 (183.1)*
Lung Reference Reference
Stages
Prior to treatment 23.6 (4.7)** 480.2 (72.3)**
During treatment 10.2 (4.7)** 252.4 (72.3)**
After treatment Reference Reference
*p < 0.05.
**p < 0.01.
SE ¼ standard error.experienced side effects such as oral dryness and difﬁculty in
chewing and swallowing. SMD-2 treatments signiﬁcantly reduced
these side effects, decreased the patients' pain, and increased the
patients' energy levels and appetite (data not shown). According to
Chinese medicine, an imbalance between “Yin and Yang (陰陽 yın
yang)” will cause disease. SMD-2 was used to treat symptoms
including damage to the lungs and stomach, “ﬂuid-humor
depletion (津液不足 jın ye bù zú)”, “dry throat and thirst (口乾作
渴 kǒu gan zuo ke)”, and “dry cough with low phlegm production
(乾咳少痰 gan ke shǎo tan)”. Seki et al13 showed that patients
who underwent radiotherapy exhibited “ﬁre due to Yin deﬁciency
(陰虛火旺 yın xu huǒ wang)”. After receiving chemotherapy, pa-
tients exhibited a “deﬁciency of Qi and Yin (陰氣兩虛 qì yın liǎng
xu)”. Patients who were terminally ill had a “deﬁciency of both Yin
and Yang (陰陽兩虛 yın yang liǎng xu)”. Radiotherapy produces
excessive heat “Yin (陰 yın)” in cancer patients, and this heat cannot
be released in a timely manner. When cancer patients undergoing
chemoradiotherapy were evaluated using the diagnostic methods
of traditional Chinese medicine (中醫 zhong yı; TCM), typical
symptoms included “blood deﬁciency (血虛 xue xu)”, “splenic
asthenia (脾虛 pí xu)”, and “stagnation of liver Qi (肝鬱氣滯 gan yù
qì zhì)”. Therefore, there are imbalances in Qi and blood, which
result in severe damage to the liver and kidney.
Most TCM remedies are mixtures of diverse herbs. The goal of
“reverse phytochemistry” is to isolate active compounds from
different herb mixtures and combine them to create novel com-
posite products.14 According to Chinese documents, SMD-2 is
beneﬁcial for “activating blood (活血 huo xue)”, “dissolving stasis
(化瘀 hua yu)”, “clearing heat (清熱 qıng re)”, and “improving
expectoration (化痰止咳 hua tan zhǐ ke)”. In addition, SMD-2 “clears
Ying heat (清陰熱 qıng yın re)” and “cools the blood (涼血 liang
xue)” to improve removal of “Ying heat (陰熱 yın re)” from cancer
patients. The traditional use of SMD-2 is to “nourish the blood and
soothe the liver (疏肝養血 shu gan yǎng xue)”. SMD-2 not only acts
as the prescription but also reﬂects therapeutic principles. Overall,
the combined impact of SMD-2 on the three common symptoms of
cancer is to “nourish the blood (養血 yǎng xue)”, and thus “invig-
orate the spleen and soothe the liver (健脾疏肝 jian pí shu gan)” to
“disperse stagnation (散瘀 san yu)”.
Head and neck cancer is the most common cancer in Taiwan.
Overall, the survival rate among patients with advanced head and
neck cancer is often poor, because of signiﬁcant medical comor-
bidities and the development of second primary cancers, which
have been associated with both betel nut and tobacco overuse.15
Although the combination of chemotherapy and radiation ther-
apy has the advantage of different treatment modalities with
different toxicity proﬁles, chemoradiotherapy to treat cancer in the
head and neck is an aggressive method associated with major
toxicity. Patients who receive this treatment often develop variousthe two types of cancer at the three time points using the generalized estimating
Se
b (SE)
Zn/Cu
b (SE)
Se/Cu
b (SE)
29.0 (17.2) 39.0 (16.3)* 2.20 (2.07)
Reference Reference Reference
70.4 (7.54)** 93.2 (10.9)** 17.3 (1.67)**
44.1 (7.54)** 75.3 (10.9)** 14.6 (1.67)**
Reference Reference Reference
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cancer patients sampled in a previous study used some form of
complementary and alternative medicine (CAM;補充與替代醫學 bǔ
chong yǔ tì dai yı xue), with the most common therapies being
relaxation/meditation techniques, spiritual or faith healing, me-
dicinal teas, reﬂexology, aromatherapy, herbal therapy, and vitamin
or mineral therapy.17 CMHs are sometimes used as an adjunct to
radiotherapy or chemotherapy for cancer. Evidence from current
studies is weakened by methodological limitations. Because of
conﬂicting reports, it is difﬁcult to argue for or against the use of
CMH as a treatment for cancer.1,18 The majority of studies have
shown that CMH improved treatment side effects and performance
status, and some have provided evidence of tumor regression and
increased survival.19 Seven randomized controlled trials have been
conducted comparing chemotherapy with or without Chinese
herbs in 542 female breast cancer patients in China. Three trials
indicated an improvement in white blood cells in the group
receiving CMH. Two showed an increase in percentage changes in
T-lymphocyte subsets CD4 and CD8. One study showed a statisti-
cally signiﬁcant difference in percentage changes in T-lymphocyte
subsets CD3, CD4, and CD8 associated with TCM.1 Although these
studies did not investigate speciﬁc components of CMH, these
supplements may have a role in stimulating immunological func-
tion in cancer patients. Consistent with this concept, SMD-2 can be
used to modify imbalances in Qi and blood and repair cell damage
to ensure maintenance of optimal immunity. Our patients using
SMD-2 treatment had increases in body weight and reported im-
provements in quality of life with regard to sleep deprivation and
anorexia (data not shown). Therefore, side effects or symptoms in
cancer patients using chemoradiotherapy can be alleviated, rein-
forcing normal diet intake and mediating their body functions. Seki
et al13 hypothesized that if cancer patients for whom “Yin and Yang
are deﬁcient (陰陽兩虛 yın yang liǎng xu)” were treated with “Yang
and Qi tonics (補陽益氣 bǔ yang yì qì)” during the day, sympathetic
activation of natural killer cells would increase, thus improving
defense against malignant cells.13
In this study, trace elements of SMD-2 were analyzed using ICP/
MS. We found that magnesium (Mg; 47,440 mg/g) was present at
the highest levels, followed by potassium (K; 25,265 mg/g) and
calcium (Ca; 12,591 mg/g). The level of Zn presentwas 85.7 mg/g. The
levels of Cu and Se were considerably limited. In our SMD-2
treatment study, we did not ﬁnd a great increase in levels of trace
elements in urine. However, a threefold increase in the urinary Zn
levels and a 10-fold increase in the Zn/Cu ratio were detected after
head and neck cancer patients were treated with chemo-
radiotherapy. In this study, Zn also had an effect in improving the
healing process for patients with mucositis and dermatitis caused
by radiation. It has been previously shown that Zn plays a signiﬁ-
cant role in the context of metabolic response to injury and wound
healing,20 but its role in the healing of radiation-related mucositis
and dermatitis is not entirely clear. However, Zn is known to be
required by > 80 different enzymes including alcohol dehydroge-
nase, carbonic anhydrase, DNA and RNA polymerase, and
carboxypeptidase. Consequently, when elevated levels of Zn are
present, tumors may continue to grow despite the lack of new
vessel formation, which may result in necrosis. These ﬁndings
could explain the presence of elevated Zn levels in secondary liver
metastases compared with primary colorectal tissues.21 Moreover,
a recent study by Rudolf et al22 has shown that Zn has the potential
to be used in chemoprevention of advanced colorectal carcinoma.
Zn may help suppress free radicals through metallothionein syn-
thesis, act as an inhibitor of the nicotinamide adenine dinucleotide
phosphate (reduced)-dependent lipid peroxidation, and prevent
lipid peroxidation by inhibition of glutathione depletion.23 How-
ever, Cu can interfere with Zn absorption by competing for bindingsites on the albumin molecule in the intravascular space.12 Inter-
estingly, our ﬁndings also indicated a statistically signiﬁcant four-
fold decrease in urinary Cu levels after cancer patients were treated
with chemoradiotherapy. The absorption of Cu into the human
body is a complicated process, depending on various factors and
dietary components. Excess Cu has been known to be a potent
oxidant, causing the generation of radical oxygen species in cells. In
addition, a study in Taiwan by Kuo et al24 showed that Cu levels in
serum and tumor cells have been reported to be signiﬁcantly
elevated in cancer patients compared with healthy individuals.
There are some limitations to this study. First, this was not a
randomized clinical experiment. Because of ethical considerations,
no placebo group was included in the study. Eighty percent of the
participants were head and neck cancer patients. All cancer pa-
tients were monitored for urinary metal levels at three time points
during the SMD-2 treatment period. The difference between uri-
nary metal levels was measured in two cancer patient groups un-
dergoing SMD-2 treatment to account for the two types of cancer
and individual variability. Urinary creatinine was not measured in
this study. Because urinary metal levels were measured at three
points over 8 weeks, we assumed a stable urinary creatinine level in
each cancer patient. Second, no accurate measure of intake of trace
elements from other sources was recorded during cancer treat-
ment. Each cancer patient may alleviate the side effects from che-
moradiotherapy using SMD-2, as well as Zn and Se from various
other sources. These trace elements can repair damaged cells and
boost immune function. However, we observed that urinary Zn and
Se levels in cancer patients using SMD-2 signiﬁcantly increased. In
addition, due to the small sample size and limited follow-up time,
further research is necessary to elucidate the active ingredients of
SMD-2 and their pharmacological activities, toxicity, and clinical
efﬁcacy.
5. Conclusion
SMD-2 treatments signiﬁcantly increased Zn and Se levels in the
urine samples from head and neck cancer patients, which will
strengthen their immune system. We conclude that increased Zn
and Se may account for the anticancer activity of SMD-2, which has
been used for a number of years in traditional medicine to promote
resistance to cancer. These ﬁndings may provide a basis for the
isolation and identiﬁcation of more highly effective anticancer
components.
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